EUVIMEDEUVIMED entdecken
Open Access

Nitric Oxide-Releasing Topical Treatments for Cutaneous Melanoma

Quincy E Grayton iD, Heba El-Ahmad, Anna L Lynch, Mikaylin E Nogler, Shannon M Wallet, Mark H Schoenfisch iD

Molecular Pharmaceutics · 04.11.2024 · 21 (11) · 5632-5645

DOI: 10.1021/acs.molpharmaceut.4c00618 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 01.10.2024. Verfasst von Quincy E Grayton und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States. Hauptthemen laut MEDLINE: Skin Neoplasms, Nitric Oxide, Hyaluronic Acid, Melanoma. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, National Science Foundation, National Institute of Diabetes and Digestive and Kidney Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Melanoma is an aggressive skin cancer notorious for high levels of drug resistance. Additionally, current treatments such as immunotherapies are often associated with numerous adverse side effects. The use of nitric oxide (NO) may represent an attractive treatment for melanoma due to NO's various anticancer properties, unlikeliness to foster resistance, and limited toxicity toward healthy tissues. The anticancer effects of chemical NO donors have been explored previously but with limited understanding of the needed characteristics for exerting optimal antimelanoma activity. Herein, the in vitro therapeutic efficacy of three macromolecular NO donor systems (i.e., cyclodextrin, mesoporous silica nanoparticles, and hyaluronic acid) with tunable NO-release kinetics was explored by evaluating skin permeation along with toxicity against melanoma and healthy skin cells. Cytotoxicity against melanoma cells was dependent on NO payload and not donor identity or NO-release kinetics. In contrast, cytotoxicity against healthy cells was primarily influenced by the macromolecular NO donor, with cyclodextrin- and hyaluronic acid-based NO donors having the highest therapeutic indices. In vitro skin permeation was influenced by both the size and charge of the NO donor, with smaller, more neutral donors resulting in greater permeation. A Pluronic F127 organogel was optimized for the delivery of a cyclodextrin-based NO donor. Delivery of the NO donor in this manner resulted in increased in vitro skin permeation and reduced tumor growth in an in vivo model.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Skin NeoplasmsNitric OxideHyaluronic AcidMelanomaNitric Oxide DonorsNanoparticlesAnimalsHumansMiceCell Line, TumorCyclodextrinsAdministration, CutaneousSkinSkin AbsorptionSilicon DioxidePoloxamerAdministration, TopicalAntineoplastic AgentsFemaleCutaneous Malignant Melanoma

Stichwörter der Autor:innen

cyclodextrinhyaluronic acidmelanomamesoporous silica nanoparticlesnitric oxidetopical delivery

Substanzen

Nitric OxideHyaluronic AcidNitric Oxide DonorsCyclodextrinsSilicon DioxidePoloxamerAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Chemistry, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
  • Department of Oral Biology, University of Florida, Gainesville, Florida 32610, United States.
  • UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.

ORCID-Profile: Quincy E Grayton, Mark H Schoenfisch

Förderung

  • NIDDK NIH HHS
  • National Science Foundation
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Grayton, Q. E., El-Ahmad, H., Lynch, A. L., Nogler, M. E., Wallet, S. M., & Schoenfisch, M. H. (2024). Nitric Oxide-Releasing Topical Treatments for Cutaneous Melanoma. Molecular Pharmaceutics, 21(11), 5632-5645. https://doi.org/10.1021/acs.molpharmaceut.4c00618

Vancouver

Grayton QE, El-Ahmad H, Lynch AL, Nogler ME, Wallet SM, Schoenfisch MH. Nitric Oxide-Releasing Topical Treatments for Cutaneous Melanoma. Molecular Pharmaceutics. 2024;21(11):5632-5645. doi:10.1021/acs.molpharmaceut.4c00618

BibTeX
@article{Grayton2024,
  author = {Grayton, Quincy E and El-Ahmad, Heba and Lynch, Anna L and Nogler, Mikaylin E and Wallet, Shannon M and Schoenfisch, Mark H},
  title = {Nitric Oxide-Releasing Topical Treatments for Cutaneous Melanoma},
  journal = {Molecular Pharmaceutics},
  year = {2024},
  volume = {21},
  number = {11},
  pages = {5632--5645},
  doi = {10.1021/acs.molpharmaceut.4c00618}
}
Kostenlos starten →